Intranasal vaccine developer Meissa Vaccines has announced that Martin Moore is stepping down as the company’s CEO and Frank Glavin has joined the company as the new Chief Executive Officer. Moore will stay with Meissa as Chief Scientific Officer. Glavin was most recently CEO of Orphan Technologies and was previously Head of Neovii Biotech North America.
Meissa has two vaccine candidates in Phase 1 clinical development: an intranasal vaccine against COVID-19 (MV-014-212) and an intranasal vaccine against RSV (MV-012-968). Both are live attenuated intranasal vaccines based on the company’s AttenuBlock technology, which uses codon deoptimization to attenuate the viruses.
Moore commented, “I am excited to welcome Frank to the Meissa leadership team. We are at an important stage in Meissa’s growth, and Frank brings extensive, complementary experience in commercial planning, business development, and pipeline strategy to advance novel technologies in clinical development for regulatory approval. I look forward to continuing to work with Frank and the Meissa team to drive our platform and vaccine candidates forward.”
Glavin said, “I’ve been working closely with Marty and the team as an advisor, and I am impressed with the differentiation of Meissa’s AttenuBlock platform in the vaccine space and the tremendous progress the company has made. The initial clinical data from the RSV and COVID-19 programs demonstrate the enormous potential of Meissa’s AttenuBlock platform to develop intranasal vaccines to protect against respiratory viruses, and we look forward to completing enrollment in these studies and reporting the data in the first half of next year.”
Read the Meissa Vaccines press release.
